Microscopic Polyangiitis clinical trials
The registry lists 69 studies for Microscopic Polyangiitis across more than 10 countries. 12 are recruiting or about to start. 4 of them are mainly about Microscopic Polyangiitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-20.
Get an email when these change. Save the Microscopic Polyangiitis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Assistance Publique - Hôpitaux de Paris (11) · University of Pennsylvania (8) · University of South Florida (5) · Cambridge University Hospitals NHS Foundation Trust (4) · Novartis Pharmaceuticals (2) · Charite University, Berlin, Germany (2) · University of Oxford (2) · Hospices Civils de Lyon (2)
What is being tested here
Drugs under test in Microscopic Polyangiitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Rituximab | 3 | 7 | 13 |
| Cyclophosphamide | 1 | 2 | 3 |
| Prednisone | 1 | 1 | 2 |
| Avacopan | 1 | 0 | 1 |
| Prednisolone | 1 | 0 | 1 |
| Azathioprine | 0 | 2 | 3 |
| Mycophenolic Acid | 0 | 2 | 3 |
| Vilobelimab | 0 | 0 | 2 |
| Infliximab | 0 | 0 | 2 |
| Methotrexate | 0 | 1 | 2 |
Drug classes tested here Corticosteroids 2 open · Antimetabolites 5
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Dec 2026Iptacopan in Patients With ANCA Associated Vasculitis · Novartis Pharmaceuticals
- Dec 2026Ocular Manifestations of Granulomatosis With Polyangiitis. · Military Institute od Medicine National Research Institute
- Mar 2027Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis · Chiba University
Who these studies take
Of the 11 Microscopic Polyangiitis studies recruiting now, 7 (64%) set no upper age limit and 3 (27%) stop at 75 or younger. 6 (55%) take children under 18. 1 (9%) are for women only and 0 (0%) for men only; 2 (18%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 5 (45%) | 5 (45%) |
| 18 | 11 (100%) | 10 (91%) |
| 30 | 10 (91%) | 9 (82%) |
| 40 | 10 (91%) | 9 (82%) |
| 50 | 10 (91%) | 9 (82%) |
| 65 | 8 (73%) | 8 (73%) |
| 75 | 8 (73%) | 8 (73%) |
| 85 | 8 (73%) | 8 (73%) |
Across all 69 studies, recruiting or not: 12% stop at 75 or younger and 6% at 65; 20% take children; 3% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 69. Browse all 69 → or search them.
- Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic DiseasesRecruitingNCT07087912Phase 41 country
- Ocular Manifestations of Granulomatosis With Polyangiitis.RecruitingNCT076647091 country
- Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.Not yet recruitingNCT07451847Phase 41 country
- Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)RecruitingNCT06983821Phase 31 country
- Vasculitis Pregnancy RegistryRecruitingNCT025935651 country
- Clinical Transcriptomics in Systemic Vasculitis (CUTIS)RecruitingNCT030043262 countries
- VCRC Tissue RepositoryRecruitingNCT029670682 countries
- One-Time DNA Study for VasculitisRecruitingNCT012413053 countries
- Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated VasculitisRecruitingNCT06611696Phase 41 country
- Special Drug Use-results Survey for Long-term Use（Avacopan）RecruitingNCT067582711 country
- Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)RecruitingNCT06350110Phase 1/21 country
- Pediatric Vasculitis InitiativeRecruitingNCT020061347 countries
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesActive, not recruitingNCT05732402Phase 1/24 countries
- Iptacopan in Patients With ANCA Associated VasculitisActive, not recruitingNCT06388941Phase 215 countries
- Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPAActive, not recruitingNCT06868290Phase 28 countries
- Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated VasculitisCompletedNCT03698071Not applicable1 country
- PR3-AAV Resilient Remission or PRRRTerminatedNCT05376319Phase 21 country
- Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic PolyangiitisCompletedNCT03920722Phase 31 country
- Hydroxychloroquine in ANCA Vasculitis EvaluationTerminatedNCT04316494Phase 41 country
- Low Dose Naltrexone to Improve Physical Health in Patients With VasculitisCompletedNCT03482479Phase 22 countries
- Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the OriginatorCompletedNCT057163341 country
- Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)Active, not recruitingNCT06294236Phase 11 country
- Comparison Between a Long Term and a Conventional Maintenance Treatment With RituximabCompletedNCT02433522Phase 31 country
- Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase AntibodiesCompletedNCT03385668Phase 21 country
- Efficacy Study of Two Treatments in the Remission of VasculitisCompletedNCT00748644Phase 31 country
- Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)CompletedNCT018620681 country
- Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)CompletedNCT00647166Phase 31 country
- Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated VasculitisCompletedNCT01731561Phase 31 country
- Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)CompletedNCT00103792Phase 31 country
- Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.CompletedNCT057038021 country
- Urinary T Lymphocytes Predict Renal Flares in Patients With Inactive ANCA-associated GlomerulonephritisCompletedNCT044283981 country
- PRagmatic Analysis of Vitamin D in ANCA-Associated VasculitisCompletedNCT04280601Not applicable1 country
- Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.CompletedNCT03895801Phase 211 countries
- Urinary T Cell Biomarker for Prediction in ANCA GlomerulonephritisStatus unknownNCT043206672 countries
- Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic PolyangiitisCompletedNCT003153932 countries
- A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic PolyangitisCompletedNCT02115997Phase 41 country
- Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPATerminatedNCT03712345Phase 22 countries
- Rituximab Vasculitis Maintenance StudyCompletedNCT01697267Phase 310 countries
- Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated VasculitisCompletedNCT02169219Phase 41 country
- Low-dose Glucocorticoid Vasculitis Induction StudyStatus unknownNCT02198248Phase 41 country
- Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated VasculitisTerminatedNCT024748881 country
- Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated VasculitisCompletedNCT00987389Phase 315 countries
- VCRC Patient Contact Registry Patient-Reported Data Validation StudyCompletedNCT021909421 country
- An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic PolyangiitisCompletedNCT016135991 country
- Journey of Patients With Vasculitis From First Symptom to DiagnosisCompletedNCT034102901 country
- Belimumab in Remission of VASculitisCompletedNCT01663623Phase 320 countries
- Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up StudyTerminatedNCT015868582 countries
- The ANCA Vasculitis Questionnaire (AAV-PRO©)CompletedNCT025070241 country
- Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic PolyangiitisCompletedNCT00104299Phase 2/32 countries
- American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic VasculitisStatus unknownNCT0106620833 countries